JP2017515839A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515839A5
JP2017515839A5 JP2016567385A JP2016567385A JP2017515839A5 JP 2017515839 A5 JP2017515839 A5 JP 2017515839A5 JP 2016567385 A JP2016567385 A JP 2016567385A JP 2016567385 A JP2016567385 A JP 2016567385A JP 2017515839 A5 JP2017515839 A5 JP 2017515839A5
Authority
JP
Japan
Prior art keywords
formulation
brain
nanoparticle
polymer
hydrophilic polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515839A (ja
JP6763780B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030381 external-priority patent/WO2015175539A1/en
Publication of JP2017515839A publication Critical patent/JP2017515839A/ja
Publication of JP2017515839A5 publication Critical patent/JP2017515839A5/ja
Application granted granted Critical
Publication of JP6763780B2 publication Critical patent/JP6763780B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567385A 2014-05-12 2015-05-12 合成脳浸透遺伝子ベクターの操作 Active JP6763780B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461991920P 2014-05-12 2014-05-12
US201461991898P 2014-05-12 2014-05-12
US61/991,898 2014-05-12
US61/991,920 2014-05-12
US201462001994P 2014-05-22 2014-05-22
US62/001,994 2014-05-22
PCT/US2015/030381 WO2015175539A1 (en) 2014-05-12 2015-05-12 Engineering synthetic brain penetrating gene vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020116339A Division JP2020172534A (ja) 2014-05-12 2020-07-06 合成脳浸透遺伝子ベクターの操作

Publications (3)

Publication Number Publication Date
JP2017515839A JP2017515839A (ja) 2017-06-15
JP2017515839A5 true JP2017515839A5 (cg-RX-API-DMAC7.html) 2018-04-26
JP6763780B2 JP6763780B2 (ja) 2020-09-30

Family

ID=53264811

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016567385A Active JP6763780B2 (ja) 2014-05-12 2015-05-12 合成脳浸透遺伝子ベクターの操作
JP2020116339A Pending JP2020172534A (ja) 2014-05-12 2020-07-06 合成脳浸透遺伝子ベクターの操作

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020116339A Pending JP2020172534A (ja) 2014-05-12 2020-07-06 合成脳浸透遺伝子ベクターの操作

Country Status (6)

Country Link
US (3) US9937270B2 (cg-RX-API-DMAC7.html)
EP (1) EP3142704A1 (cg-RX-API-DMAC7.html)
JP (2) JP6763780B2 (cg-RX-API-DMAC7.html)
AU (1) AU2015259362B2 (cg-RX-API-DMAC7.html)
CA (1) CA2948844C (cg-RX-API-DMAC7.html)
WO (1) WO2015175539A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US10632080B2 (en) * 2015-09-11 2020-04-28 The Johns Hopkins University Compositions and methods to improve nanoparticle distribution within the brain interstitium
WO2020210805A1 (en) * 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
CN111658785B (zh) * 2020-04-21 2023-05-12 威爱医疗科技(中山)有限公司 一种基因载体及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
CA2406081C (en) 2000-04-26 2009-12-22 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
WO2002003848A2 (en) 2000-07-10 2002-01-17 Naito Albert T Method for opening the blood-brain barrier
CZ308053B6 (cs) 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
US7579451B2 (en) 2004-07-21 2009-08-25 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
CA2574603C (en) 2004-08-04 2014-11-04 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US20060223777A1 (en) 2005-03-29 2006-10-05 Dharmacon, Inc. Highly functional short hairpin RNA
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070123482A1 (en) 2005-08-10 2007-05-31 Markus Stoffel Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
JP5523705B2 (ja) 2005-08-29 2014-06-18 レグルス・セラピューティクス・インコーポレイテッド Ｍｉｒ−１２２ａをモジュレートする使用方法
DK1931780T3 (en) 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
EP2007889A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
JP2008053276A (ja) 2006-08-22 2008-03-06 Nec Electronics Corp 半導体装置の製造方法
WO2008046911A2 (en) 2006-10-20 2008-04-24 Exiqon A/S Novel human micrornas associated with cancer
US20090137504A1 (en) 2006-12-21 2009-05-28 Soren Morgenthaler Echwald Microrna target site blocking oligos and uses thereof
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2646107A2 (en) * 2010-12-01 2013-10-09 Spinal Modulation Inc. Agent delivery systems for selective neuromodulation
US9327037B2 (en) * 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
BR112014019431A8 (pt) * 2012-02-07 2017-07-11 Global Bio Therapeutics Usa Inc Método compartimentalizado de distribuição de ácido nucleico e composições e usos desses

Similar Documents

Publication Publication Date Title
Petkar et al. Nanostructured materials in drug and gene delivery: a review of the state of the art
da Silva et al. New perspectives in nanotherapeutics for chronic respiratory diseases
AU2016200683B2 (en) Nanoparticles with enhanced mucosal penetration or decreased inflammation
TWI644674B (zh) 治療性聚合奈米粒子及其製造及使用方法
Ghalamfarsa et al. Application of nanomedicine for crossing the blood–brain barrier: Theranostic opportunities in multiple sclerosis
Liu et al. Dendrimers in oral drug delivery application: current explorations, toxicity issues and strategies for improvement
Shah et al. Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders
JP2017515839A5 (cg-RX-API-DMAC7.html)
Mayilsamy et al. Treatment with shCCL20-CCR6 nanodendriplexes and human mesenchymal stem cell therapy improves pathology in mice with repeated traumatic brain injury
Zhao et al. Intranasal immunization with O-2′-Hydroxypropyl trimethyl ammonium chloride chitosan nanoparticles loaded with Newcastle disease virus DNA vaccine enhances mucosal immune response in chickens
JP2018533579A5 (cg-RX-API-DMAC7.html)
Chandra et al. Combining unique properties of dendrimers and magnetic nanoparticles towards cancer theranostics
JP2016522833A (ja) 医薬組成物、その製造および使用
Xin et al. Evaluation of rMETase-loaded stealth PLGA/liposomes modified with anti-CAGE scFV for treatment of gastric carcinoma
US20170258718A1 (en) Pharmaceutical composition, preparation and uses thereof
WO2016128591A1 (es) Procedimiento de obtención de una composición farmacéutica de nanopartículas poliméricas para el tratamiento del dolor neuropático producido por compresión nerviosa periférica
CN110139826A (zh) 具有负的表面电荷的微粒和纳米颗粒
Ravinayagam et al. Nanomaterials and their negative effects on human health
Edward Werner et al. Chemoradiotherapy of human tumors: novel approaches from nanomedicine
ES2872552T3 (es) Nanopartículas poliméricas y métodos de preparación y de uso de las mismas
JP2018534244A5 (cg-RX-API-DMAC7.html)
CN112566627A (zh) 用于递送病毒的高分子纳米粒子组合物及其制造方法
Rathi et al. Treatment of tuberculosis in nano era: recent avenues
CN118697901A (zh) 一种吸入式IL-10 mRNA纳米制剂及其制备方法和应用
Roy Targeted drug delivery systems used in dentistry-A short review.